SARS-CoV-2 seroprevalence and antibody trajectories after easing of COVID-19 restrictions: a longitudinal study in China.

Front Public Health · 2024 · PMC11650369 · PMID 39691651

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a slightly increasing trendno p-value reported

Overall, the adjusted seroprevalence (95% CI) was 93.51% (92.89–94.11%) at baseline and 93.92% (93.30–94.50%), 94.58% (93.98–95.16%), and 94.24% (93.60–94.79%) at three follow-ups, with a slightly increasing trend.

also in 284 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.